Identification
- Summary
Hesperidin is a bioflavonoid found in a variety of nutritional supplements that is touted to have various beneficial effects on blood vessel disorders and various other conditions.
- Generic Name
- Hesperidin
- DrugBank Accession Number
- DB04703
- Background
Hesperidin is a flavan-on glycoside found in citrus fruits.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Hesperidin (DB04703)
- Weight
- Average: 610.5606
Monoisotopic: 610.189770418 - Chemical Formula
- C28H34O15
- Synonyms
- (S)-(−)-hesperidin
- Cirantin
- Ciratin
- Hesperetin 7-O-rutinoside
- Hesperidin
- Hesperidina
- Hesperidoside
- External IDs
- NDI 590
- NSC-44184
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UAurora kinase B regulatorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AVEFLON TABLET Hesperidin (50 mg) + Diosmin (450 mg) Tablet, film coated Oral APEX PHARMACY MARKETING SDN. BHD. 2020-09-08 Not applicable Malaysia 
Cilobana Cpa Tab Hesperidin (75 mg / tab) + Ascorbic acid (150 mg / tab) + Bromelains (4 mg / tab) + Citrus bioflavonoids (75 mg / tab) + Vitamin A (10000 unit / tab) Tablet Oral Anabolic Laboratories Inc. 1968-12-31 1996-10-02 Canada 
Daflon 1000mg Film-Coated Tablet Hesperidin (100 mg) + Diosmin (900 mg) Tablet, film coated Oral SERVIER MALAYSIA SDN BHD 2020-09-08 Not applicable Malaysia Daflon 500 mg - Filmtabletten Hesperidin (50 mg) + Diosmin (450 mg) Tablet, film coated Oral Servier Austria Gmb H 1994-11-18 Not applicable Austria 
daflon 500mg tablets Hesperidin (50 mg) + Diosmin (450 mg) Tablet, film coated Oral SERVIER MALAYSIA SDN BHD 2020-09-08 Not applicable Malaysia DAFLON TABLET 500 mg Hesperidin (50 mg) + Diosmin (450 mg) Tablet, sugar coated Oral SERVIER (S) PTE LTD 1988-05-12 Not applicable Singapore Davmorid Film Coated Tablet Hesperidin (50 mg) + Diosmin (450 mg) Tablet, film coated Oral Y.S.P. INDUSTRIES (M) SDN BHD 2020-09-08 Not applicable Malaysia DIOFLEX TABLET Hesperidin (50 mg) + Diosmin (450 mg) Tablet Oral PRIME PHARMACEUTICAL SDN. BHD. 2020-09-08 Not applicable Malaysia DIOKERN 450 MG/50 MG FILM KAPLI TABLET,30 ADET Hesperidin (50 mg) + Diosmin (450 mg) Tablet, coated Oral DROGSAN İLAÇLARI SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey 
DIOKERN 450 MG/50 MG FILM KAPLI TABLET,60 ADET Hesperidin (50 mg) + Diosmin (450 mg) Tablet, coated Oral DROGSAN İLAÇLARI SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as flavonoid-7-o-glycosides. These are phenolic compounds containing a flavonoid moiety which is O-glycosidically linked to carbohydrate moiety at the C7-position.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Flavonoids
- Sub Class
- Flavonoid glycosides
- Direct Parent
- Flavonoid-7-O-glycosides
- Alternative Parents
- 4'-O-methylated flavonoids / 3'-hydroxyflavonoids / 5-hydroxyflavonoids / Flavanones / Phenolic glycosides / O-glycosyl compounds / Disaccharides / Chromones / Methoxyphenols / Phenoxy compounds show 14 more
- Substituents
- 1-benzopyran / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 3'-hydroxyflavonoid / 4p-methoxyflavonoid-skeleton / 5-hydroxyflavonoid / Acetal / Alcohol / Alkyl aryl ether / Anisole show 33 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- rutinoside, disaccharide derivative, 3'-hydroxyflavanones, monomethoxyflavanone, flavanone glycoside, dihydroxyflavanone (CHEBI:28775) / flavanones (C09755)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- E750O06Y6O
- CAS number
- 520-26-3
- InChI Key
- QUQPHWDTPGMPEX-QJBIFVCTSA-N
- InChI
- InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1
- IUPAC Name
- (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-3,4-dihydro-2H-1-benzopyran-4-one
- SMILES
- COC1=CC=C(C=C1O)[C@@H]1CC(=O)C2=C(O1)C=C(O[C@@H]1O[C@H](CO[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]1O)C=C2O
References
- Synthesis Reference
Hiromi Hijiya, Toshio Miyake, ".alpha.-glycosyl hesperidin, and its preparation and uses." U.S. Patent US5652124, issued June, 1983.
US5652124- General References
- Not Available
- External Links
- KEGG Drug
- D01038
- KEGG Compound
- C09755
- PubChem Compound
- 10621
- PubChem Substance
- 46506898
- ChemSpider
- 10176
- BindingDB
- 61776
- 5281
- ChEBI
- 28775
- ChEMBL
- CHEMBL449317
- ZINC
- ZINC000008143568
- PharmGKB
- PA449867
- PDBe Ligand
- H1N
- Wikipedia
- Hesperidin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Lymphedema Lower Extremity 1 4 Completed Treatment Venous Insufficiency 1 4 Not Yet Recruiting Treatment Pelvic Congestive Syndrome / Pelvic Varicose Veins / Venous Disease 1 3 Completed Prevention Osteoporosis, Osteopenia 1 3 Not Yet Recruiting Prevention Vinca Alkaloid Adverse Reaction 1 3 Unknown Status Treatment Chronic Venous Insufficiency (CVI) / Disease 1 2 Completed Treatment Abdominal Pain / Chest Pain / Confusion / Coronavirus Disease 2019 (COVID‑19) / Cough / Dyspnea / Fever / Headache / Irritability / Joint Pain / Loss of smell / Muscle Weakness / Myalgia / Nausea / Pain / Sore Throat / Vomiting 1 2 Unknown Status Treatment Endothelial Dysfunction / Syndrome, Metabolic 1 2 Withdrawn Treatment Obesity / Resistance, Insulin 1 1 Completed Basic Science Bioequivalence 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, film coated Oral Suspension Oral 1000 mg Tablet, sugar coated Oral 450 mg Tablet, coated Oral Tablet Oral 450 mg Tablet, coated Oral 500 mg Tablet Oral Tablet, film coated Tablet, extended release Oral Capsule, liquid filled Oral 500 mg Tablet, film coated Oral 450 mg Capsule Oral Powder, for suspension Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.69 mg/mL ALOGPS logP -0.27 ALOGPS logP -0.31 Chemaxon logS -2.4 ALOGPS pKa (Strongest Acidic) 8.61 Chemaxon pKa (Strongest Basic) -3.6 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 15 Chemaxon Hydrogen Donor Count 8 Chemaxon Polar Surface Area 234.29 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 140.77 m3·mol-1 Chemaxon Polarizability 58.87 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Regulator
- General Function
- Protein serine/threonine/tyrosine kinase activity
- Specific Function
- Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in...
- Gene Name
- AURKB
- Uniprot ID
- Q96GD4
- Uniprot Name
- Aurora kinase B
- Molecular Weight
- 39310.195 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- de Groot CO, Hsia JE, Anzola JV, Motamedi A, Yoon M, Wong YL, Jenkins D, Lee HJ, Martinez MB, Davis RL, Gahman TC, Desai A, Shiau AK: A Cell Biologist's Field Guide to Aurora Kinase Inhibitors. Front Oncol. 2015 Dec 21;5:285. doi: 10.3389/fonc.2015.00285. eCollection 2015. [Article]
Drug created at September 11, 2007 17:49 / Updated at April 30, 2021 13:05